Stocks should rally if the U.S. and China agree to new negotiations and a ceasefire in the trade war, but the economic impact of tariffs will continue.Market Insiderread more
More than 300 companies are talking to government officials in Washington about how detrimental the trade war is.Marketsread more
Powell stresses the central bank's independence in a speech that comes amid continuous pressure from the White House to cut interest rates.The Fedread more
The trade war between Beijing and Washington appears to have depressed Chinese property purchases in the United States. China's own actions may also be playing a role.Real Estateread more
Stocks in Asia were set to open lower on Wednesday after Federal Reserve Chairman Jerome Powell tempered expectations for a potential interest rate cut.Asia Marketsread more
In a text message, Grisham confirmed to CNBC that she will still be working for the first lady even as she takes on her new roles.Politicsread more
Acting Customs and Border Protection Commissioner John Sanders is resigning amid the furor over the Trump administration's treatment of migrant children.Politicsread more
NBC is taking the office back from Netflix as it seeks to bolster its own streaming service launching in 2020.Technologyread more
Wayfair employees plan to walk out tomorrow, after no action was taken in response to their opposition to the company supplying border detention camps with beds for children.Retailread more
Micron beat analyst estimates on earnings and revenue for its fiscal third quarter of 2019.Technologyread more
Omarosa Manigault Newman, who had been a senior advisor to President Donald Trump before her firing, was sued for allegedly failing to file required financial disclosures.Politicsread more
The news flow around once-embattled drugmaker Valeant has been quiet lately. And that may be exactly what CEO Joe Papa is aiming for.
But on Tuesday, he said Valeant plans to meet a major milestone this week: It will pay off an additional $125 million in debt, exceeding a goal set in August 2016 to pay down $5 billion in debt by February 2018. The company still has a significant debt load — more than $26 billion — but no obligations until 2020, Papa said in an interview.
"We've over-delivered on strong cash flow, and we were also able to sell assets at double-digit multiples," Papa told CNBC.
The company has divested the cancer drug Provenge, skin-care businesses Obagi and Cerave, and a unit called iNova to aid in its debt sales. The Obagi sale hasn't yet closed and isn't included in the debt paydown announced Tuesday.
The moves come after a tumultuous year for Valeant that saw its stock crater from a high of more than $250 a share in mid-2015 to less than $10 as the company's business practices came into question. Valeant was held up, along with Martin Shkreli, as an example of excessive drug price increases, and its management resigned. Its debt obligations have weighed heavily on the stock.
Valeant shares are still trading at a tiny fraction of their all-time high, closing Monday at $11.41.
Papa emphasized that as Valeant divested units, it was able to keep its "core" franchises: the Bausch + Lomb eye care business, the Salix unit in gastrointestinal products, and its dermatology unit.
"We did get some inbound interest" on those assets, Papa said. "We have to listen because we still have a lot of debt," but the company wouldn't sell them for less than it perceives them to be worth, he said.
Some of Valeant's asset sales did come at prices lower than what the company originally paid for them: Obagi's sale, announced in July for $190 million, was at least $150 million less than what Valeant paid for it in 2013. But Valeant acquired Provenge-maker Dendreon out of bankruptcy in early 2015 for $495 million, and in January announced its sale for $820 million.
Papa said "the metrics are reset" in terms of assets. The previous management team, led by CEO Mike Pearson, built the company through a series of acquisitions at valuations many now question.
As for Valeant's future growth, Papa said acquisitions aren't the plan.
"Right now we're really focused on growing our business organically," he said. Drug price increases will be limited to less than 10 percent a year.
"We're really excited about the progress we've made."